February 18, 2015
By Mark Terry, BioSpace.com Breaking News Staff
Aurobindo Pharma USA , a subsidiary of India-based Aurobindo Pharma Limited, announced yesterday that it will be building a new manufacturing and distribution center in New Jersey.
The company acquired 90 acres on Windsor Center Drive in East Windsor, N.J. It is close to the 43,000-square-foot Patscentre building, which is used by Novo Tech, a pharmaceutical research and development company. Aurobindo indicates the new facility will create at least 300 new jobs when it goes live.
“We are excited that Aurobindo has chosen East Windsor for their new warehouse and distribution center, bringing new tax dollars and new jobs to our community,” said East Windsor Mayor Janice Mironov in a statement. “This expansion here by Aurobindo, a global corporation, represents the attraction to East Windsor of another high-tech, high-growth potential company in our Einstein’s Alley corridor.”
Einstein’s Alley is a non-profit, private economic development initiative in central New Jersey. One of the Alley’s clusters is Bio/Pharmaceuticals and Life Sciences Industry, which accounts for about five percent of New Jersey’s Gross Domestic Product. The cluster has three components, the pharmaceutical sector, which accounts for 44.2 percent, biotechnology, accounting for 34.1 percent, and medical device manufacturing, accounting for 21.6 percent. Other clusters include Transportation, Logistics, Distribution Industry and Finance Industry.
Aurobindo USA has a broad portfolio of generic drugs that includes more than 125 product families and 450 individual product packages. In addition to global production, the company currently runs two facilities in central New Jersey for a total of about 300,000 square feet of laboratory, manufacturing, distribution and administrative space.
Aurobindo Pharma Limited recently recently announced that it expects a minimum of 25 injectable drugs will be soon approved by the U.S. Food and Drug Administration (FDA) this year. The company has about 45 filings pending in this area.
The company indicates it hopes the injectables business to grow by 50 percent this year and continue at a similar rate for several years to come. The injectables business has brought in about $50 million for the nine-month period ending December 2014.
“We at Aurobindo Pharma are very excited about our recent acquisition and planned expansion into East Windsor,” said Robert Cunard, chief executive officer of Aurobindo Pharma in a statement.“We have appreciated the valuable assistance and guidance of the mayor and her team, who have been great partners and extremely helpful to our company in moving forward with our acquisition and planned expansion. We look forward to a long and successful collaboration, and becoming a member of the East Windsor business community.”
BioSpace Temperature Poll
Will Job Cuts Continue? After a week that saw Quintiles, Sanofi and Actavis slashing almost a 1,000 biotech jobs, BioSpace wonders if the ax will continue to fall. Give us your thoughts about the sector’s “streamlining” below.
